

PATENT COOPERATION TREATY

PCT
NOTIFICATION OF ELECTION
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year) 07 November 2001 (07.11.01)	
International application No. PCT/GB00/02257	Applicant's or agent's file reference N77399NPMR
International filing date (day/month/year) 09 June 2000 (09.06.00)	Priority date (day/month/year) 16 July 1999 (16.07.99)
Applicant KENDALL, Mark, Anthony, Fernance et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
12 February 2001 (12.02.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Juan CRUZ Telephone No.: (41-22) 338.83.38
---	---

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05455 A1

(51) International Patent Classification⁷: **A61M 5/30**

(21) International Application Number: **PCT/GB00/02257**

(22) International Filing Date: **9 June 2000 (09.06.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
9916800.7 **16 July 1999 (16.07.1999) GB**

(71) Applicant (for all designated States except US): **POWDERJECT RESEARCH LIMITED [GB/GB]**; The Oxford Science Park, 4 Robert Robinson Avenue, Oxford OX4 4GA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KENDALL, Mark,**

Anthony, Fernance [AU/GB]; PowderJect Research Limited, The Oxford Science Park, 4 Robert Robinson Avenue, Oxford OX4 4GA (GB). **BROWN, Garry [AU/GB]**; PowderJect Research Limited, The Oxford Science Park, 4 Robert Robinson Avenue, Oxford OX4 4GA (GB).



(74) Agents: **PRICE, Nigel, John, King et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: **NEEDLELESS SYRINGE**



(57) Abstract: The invention provides a device which seeks to ensure that substantially all the particles delivered avoid interaction with the so-called "starting process". There is provided a needleless injection device comprising a driver chamber (51) arranged, in use, to contain a charge of pressurised gas, a duct section (52) connected to the driver chamber (51) to receive gas therefrom and a closure means (53) for preventing the flow of gas from the driver chamber (51) to the duct section (52) until the closure means (53) is opened. Further, a dose of particles (58) is positioned within the device in the region of the closure means (53). The device is so constructed and arranged that upon opening of the closure means (53), a primary shock wave is produced to travel along the duct (52) in a downstream direction so that a substantially quasi-steady gas flow is established in the duct (52) upstream of the primary shock wave, with the dose of particles (58) being substantially wholly entrained in the substantially quasi-steady flow to be accelerated thereby and expelled from the device.

WO 01/05455 A1



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

Published:

— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NEEDLELESS SYRINGE

The present invention relates generally to a needleless syringe device for accelerating particles for delivery into target tissue of a subject.

5 The ability to deliver pharmaceuticals through skin surfaces (transdermal delivery) provides many advantages over oral or parenteral delivery techniques. In particular, transdermal delivery provides a safe, convenient and non-invasive alternative to traditional drug administration systems, conveniently avoiding the major problems associated with oral delivery (e.g. variable rates of absorption and
10 metabolism, gastrointestinal irritation and/or bitter or unpleasant drug tastes) or parenteral delivery (e.g. needle pain, the risk of introducing infection to treated individuals, the risk of contamination or infection of health care workers caused by accidental needle-sticks and the disposal of used needles). In addition, transdermal delivery affords a high degree of control over blood concentrations of administered
15 pharmaceuticals.

 Recently, a novel transdermal drug delivery system that entails the use of a needleless syringe to fire powders (i.e. solid drug-containing particles) in controlled doses into and through intact skin has been described. In particular, US Patent No. 5,630,796 to Bellhouse et al. describes a needleless syringe that delivers
20 pharmaceutical particles entrained in a supersonic gas flow. The needleless syringe can be used for transdermal delivery of powdered therapeutic compounds and compositions (e.g. drugs, vaccines, etc.), for delivery of genetic material into living cells (e.g. gene therapy) and for the delivery of biopharmaceuticals to skin, muscle, blood or lymph. The needleless syringe can also be used in conjunction with surgery
25 to deliver particles to organ surfaces, solid tumours and/or to surgical cavities (e.g. tumour beds or cavities after tumour resection). In theory, practically any pharmaceutical agent that can be prepared in a substantially solid, particulate form can be safely and easily delivered using such devices.

 One needleless syringe described in Bellhouse et al. comprises an elongate
30 tubular over-expanded converging-diverging nozzle having a rupturable membrane initially closing the passage through the nozzle and arranged substantially adjacent to the upstream end of the nozzle. Particles to be delivered are disposed adjacent to the

rupturable membrane and are delivered using an energising means which applies a gaseous pressure to the upstream side of the membrane sufficient to rupture the membrane and produce a supersonic gas flow (containing the pharmaceutical particles) through the nozzle for delivery from the downstream end thereof.

5 Transdermal delivery using the needleless syringe described in Bellhouse et al. is carried out with particles having an approximate size that generally ranges from between 0.1 and 250 μm . For drug delivery, an optimal particle size is usually at least about 10 to 15 μm (the size of a typical cell). For gene delivery, an optimal particle size is generally substantially smaller than 10 μm . Particles larger than about
10 250 μm can also be delivered from the device, with the upper limitation being the point at which the size of the particles would cause untoward damage to the skin cells. The actual distance which the delivered particles will penetrate depends upon particle size (e.g. the nominal particle diameter assuming a roughly spherical particle geometry), particle density, the initial velocity at which the particle impacts the skin
15 surface, and the density and kinematic viscosity of the skin. In this regard, optimal particle densities for use in needleless injection generally range between about 0.1 and 25 g/cm^3 , preferably between about 0.8 and 1.5 g/cm^3 , and injection velocities generally range between about 100 and 3000 m/sec. These particle size and density ranges are also appropriate to the present invention.

20 There are two distinct phases of gas flow that occur in the device. The first phase is associated with the shock waves produced upon rupturing of the membrane and is called "the starting process" (or "starting transient"). The second regime of flow occurs upstream of the shock and expansion waves associated with starting process and is called quasi-steady nozzle flow.

25 As discussed in Bellhouse et al, it was considered that the particle velocity depended upon the flow in the starting process. The starting process is generated by a sudden impulse change in pressure within the divergent nozzle, and in the Bellhouse et al device is initiated at the throat of the nozzle. This is shown by the space-time ($x-t$) diagram of Figure 1. This Figure shows the distance downstream
30 (positive values of x) and upstream (negative values of x) of the nozzle exit plane (i.e. the distal end of the nozzle) along the abscissa and shows time on the ordinate. The time starts when the device is actuated. After rupturing of the membrane (which is

located at around $x=-50$) at $t=0$, a steep front of high pressure (a shock wave 11) sweeps downstream along the length of the nozzle. This is closely followed by the so-called "contact surface" 12.

The contact surface 12 is the boundary between the gases that were previously separated by the membrane. It is well acknowledged that the gases do not mix appreciably at this boundary so the effect is one of the driver gas (the gas upstream of the membrane before rupturing) "pushing" the driven gas (the gas downstream of the membrane before rupturing) out of the nozzle like a piston, with the contact surface 12 being analogous to the face of the piston. The contact surface 12 is closely followed by a secondary shock wave 13. The secondary shock wave 13 is followed by a series of oblique shock fronts 16 within a starting process (region 1 in Figure 1) with large variations in gas density and velocity (and therefore particle velocity). The starting process region 1 is substantially bounded by the shocks 11, 14 and 15; shock front 15 is mentioned further below.

The starting process is followed by a regime of quasi-steady flow (in region 3). The quasi-steady flow is clean, that is to say substantially free of shock waves such that the velocity at a given point changes slowly enough with time to be accurately modelled by steady flow non time-varying equations. Quasi-steady flow is thus different from truly steady flow in which the Mach number at a given point does not change over time, and unsteady flow in which the Mach number at a given point varies, and the flow is governed by unsteady equations. Both the starting process and quasi-steady flow are terminated by an oblique shock front 15 that is swept upstream of the nozzle exit, as a result of over-expanded nozzle operation. This shock marks the boundary of region 2. As is mentioned in Bellhouse et al, it was thought that the particles, being initially positioned on, or very near to, the rupturable membrane, travelled with the contact surface 12 between the fronts of the primary and secondary shock waves 11,13. In the light of investigations by the present inventors, this view is now believed to be over-simplistic and (as is discussed later) the gas-particle flow in such prior art devices is more complicated with groups of particles being accelerated by different mechanisms. It is still true that the starting process is critical to the acceleration of a proportion of the particles in prior art

devices. In contrast to this, the essence of the present invention is based on the idea of trying to avoid entraining the particles in the starting process.

Previous devices have utilised over-expanded nozzles which have an exit cross-sectional area A_e greater than the exit cross-sectional area of a correctly-expanded nozzle $A_{correct}$. Over-expanded operation occurs when the ratio P_{tot}/P_e of the total pressure P_{tot} to the ambient exit pressure P_e is insufficient for a correctly expanded supersonic flow for a given nozzle area ratio A_1/A_e (where A_1 is the minimum diameter in the system). An overexpanded nozzle was used in prior art devices because, in order to obtain an adequate spread of payload on the target, it was thought that a large exit area was required. However, experiments have shown that using an over-expanded nozzle leads to flow non-uniformities such as oblique (or normal) quasi-stationary shock waves in the flow which serve to detach the flow from the nozzle walls. This flow accelerates the particles in a separated jet. Thus, surprisingly, it has been found that using a larger exit area does not necessarily increase the useful target area and in fact often causes the flow to detach resulting in a central jet core forming and a consequent low payload spread. This is undesirable and is known as "jetting".

Furthermore, devices of the prior art (such as those described in Bellhouse et al) utilise a convergent nozzle portion downstream of the particle-containing cassette. This portion acts as the interface between the relatively large membrane diameter and the relatively small nozzle throat diameter. The chosen throat diameter is controlled by the desired maximum choked mass flow rate through the device and the chosen membrane diameter is controlled by the need to be easily able to manufacture the cassette and hold the dose of particles required. Thus, upon actuation, the particles are forced through a constriction in the device. It is thought that this may increase particle-wall attrition and reduce the particle size and thereby undesirably affect the acceleration and penetration characteristics of the particles.

Experimental research sponsored by the present applicant has shown that the prior art devices produce two distinctive types of particle behaviour. Results from time resolved DGV (Doppler Global Velocimetry) measurements are shown in Figure 2, (see Kendall MAF, Quinlan NJ, Thorpe SJ, Ainsworth RW and Bellhouse BJ (1999), "The gas dynamics of a high speed needle-free drug delivery system",

International Symposium on Shock Waves 22, Imperial College, London, July 19-23 and Quinlan NJ, Thorpe SJ and Ainsworth RW (1999), "Time-resolved Doppler global velocimetry of gas-particle flows in transdermal powder drug delivery", 8th Int. Conf. On Laser Anemometry- Advances and Applications, 6-9 Sept, University of Rome, Italy. This shows a cross-section of the divergent portion of a nozzle and gives the instantaneous speed of the particles at a time of 177 μ s after rupture of the membrane (not shown).

As can be seen, the leading particles 21 are delivered in a wide cloud at a typical velocity of 200 - 400 m/s. A narrower quasi-steady stream of particles follows the leading cloud at 650 - 800 m/s; it should be noted that the white circular image centred on the plane of the nozzle exit together with the dark shadow on its right hand boundary as drawn is an artefact produced by this measurement technique. The leading particles are associated with the transient starting process in the gas flow, while the high speed particles are entrained in the quasi-steady nozzle flow. As has been mentioned, the nozzle in this prior art device is over-expanded which means oblique shocks will be present in the nozzle. The detachment of the high velocity particle stream from the nozzle walls is a direct consequence of the shock induced separation of the nozzle gas flow due to these shocks. Referring again to Figure 1, the gas flow has been broadly categorised into three flow regimes:

- i) The Starting Process (region 1)
- ii) Shock-Processed Flow (region 2)
- iii) Quasi-Steady Supersonic Flow (region 3)

The particle trajectories 17 are also shown in Figure 1. As can be seen, a significant proportion of the particles are accelerated within the starting process but then decelerate as they reach the secondary shock wave 13 and contact surface 12. A cloud front 18 of particles is seen to decelerate as it leaves the nozzle, the nozzle exit being represented by $x=0$. These particles are those entrained with the initial 200 - 400 m/s cloud attached to the nozzle wall. By nature, the starting process creates a flow having large variations in axial gas velocity and density. These are thought to be the two most important parameters for particle acceleration. There are also large variations in gas velocity and density radially. This flow regime is therefore considered unsuitable for drug delivery if uniform velocities and distributions are

required. Another fraction of particles do not reach the secondary shock 13 but are processed firstly by the oblique shocks 16 within the starting process (in region 1) and then the upstream moving oblique shock 15 which defines the separated flow within region 2. The final component of the particle payload is accelerated within
5 the quasi-steady flow (region 3, particle trajectories not shown in Figure), before being separated by the quasi-stationary shock front 14 (defined in region 2). This acceleration path leads to the highest particle velocity of 850 m/s confined to a separated jet of approximately 9 mm diameter.

It seems, contrary to previous beliefs, that the starting process, rather than
10 being the chief accelerator of the particles, actually acts as an impediment to high velocity particles. The particles which exit initially in a large cloud seem to act as a barrier to particles entrained in the subsequent quasi-steady flow resulting in lower overall particle velocities, which can be undesirable.

The present invention arises from the idea that, if one can prevent the
15 particles from being entrained in the starting process flow, then substantially all of the particles will be entrained in the subsequent quasi-steady supersonic flow, resulting in higher and more uniform particle velocities. The present invention also alleviates the problem of "jetting" by using a substantially correctly expanded nozzle and the problem of particle attrition by dispensing with a convergence downstream of
20 the membrane.

Accordingly, the present invention includes a method of accelerating a dose of particles in a needleless injection device having a driver chamber and a duct section downstream of said driver chamber, the method comprising:

25 opening closure means located between said driver chamber and said duct section;

producing a primary shock wave travelling in a downstream direction in said duct section;

establishing a substantially quasi-steady flow of fluid in said duct section
30 upstream of said primary shock wave; and

entraining and accelerating substantially all the dose of particles in said substantially quasi-steady flow for the duration of time that said particles are in said duct section.

In accordance with preferred embodiments of the method, a starting process
5 is created when the primary shock wave reaches the downstream end of the duct. A secondary shock wave may also be produced behind the primary shock wave and the quasi-steady flow is preferably established upstream of the secondary shock wave, and continues after the secondary shock wave has passed out of the device.

The present invention also includes a needleless injection device comprising:
10 a driver chamber arranged, in use, to contain a charge of pressurised gas;
a duct section connected to said driver chamber to receive gas therefrom;
closure means for preventing the flow of gas from said driver chamber to said duct section until said closure means is opened; and
a dose of particles positioned within the device in the region of said closure
15 means;

said device being so constructed and arranged that upon opening of said closure means, a primary shock wave is produced to travel along said duct section in a downstream direction and a substantially quasi-steady gas flow is established in said duct section upstream of said primary shock wave, said dose of particles being
20 substantially wholly entrained in said substantially quasi-steady flow to be accelerated thereby and expelled from the device.

The driver chamber may be pre-charged with gas or could be connected to a source of gas operable to charge the driver chamber with pressurised gas. The driver chamber may be constituted by a constant area tube or may have a convergence at its
25 downstream end.

The duct section is advantageously of a constant cross-sectional area and the particles are usefully positioned upstream of the closure means.

Preferably, there is no convergent portion downstream of the closure means and there is a divergent portion downstream of the duct section. When such a
30 divergent portion is provided, the shock wave initiates a transient starting process upon reaching it and this transient process is followed by a quasi-steady supersonic flow in the divergent portion.

The purpose of the divergent portion is to further accelerate the entrained particles in a controlled manner. The divergent portion preferably has an area ratio such that flow there through is substantially correctly expanded and may also be contoured to prevent oblique shock waves forming in the divergence and/or to
5 provide a uniform distribution of particles.

A further closure means may be provided and this or the first said closure means may comprise a rupturable membrane. When two closure means are used, the particles are advantageously positioned between them and each closure may have the same or different opening pressures.

10 A further aspect of the invention provides a particle retention assembly of or for use in a needleless injection device; said assembly comprising:

first closure means arranged to open when the pressure across it is P_1 ; and

second closure means which, in use, is located upstream of said first closure means and which is arranged to open when the pressure across it is P_2 ;

15 wherein P_1 and P_2 are different.

In connection with this aspect, there is also provided a method of entraining a dose of particles in a gas flow in a needleless injection device, the method comprising:

opening an upstream closure means when the pressure difference thereacross
20 is P_2 to produce a cloud of gas;

entraining said particles in said cloud of gas; and

opening a downstream closure means when the downstream closure means is exposed to said cloud of gas and entrained particles and when the pressure difference across said downstream closure means is P_1 ;

25 wherein P_1 is different to P_2 .

The invention provides in a yet further aspect a particle retention assembly of or for use in a needleless injection device; said assembly comprising:

first closure means arranged to open when the pressure across it is P_1 ;

second closure means which, in use, is located upstream of said first closure
30 means and which is arranged to open when the pressure across it is P_2 ;

a transfer duct which fluidly connects a location upstream of said second closure means to a location between said first and second closure means.

Preferably, the transfer duct causes a jet to impinge on the space between the closure means so as to mix any particles located there. There may also be provided a closure in the transfer duct itself which can be arranged to open before the second closure means. The transfer duct may be positioned in the second closure means and
5 may be embodied as a small hole or score.

In connection with this aspect, there is provided a method of entraining a dose of particles in a gas flow in a needleless injection device, the method comprising:

providing a duct having upstream and downstream closure means;

providing a transfer duct which is arranged to permit gas from upstream of
10 said upstream closure means to be introduced into the space between said upstream closure means and said downstream closure means.

There is further provided in another aspect a particle retention assembly of or for use in a needleless injection device; said assembly comprising:

first closure means arranged to open when the pressure across it is P_1 ;

15 second closure means which, in use, is located upstream of said first closure means and which is arranged to open when the pressure across it is P_2 ;

wherein one of said first and second closure means are constituted by rupturable membranes which are scored or indented so as to provide controlled rupturing.

20 The scoring/indenting is preferably along radial lines of the membrane to achieve optimum controlled rupturing.

Preferably, particles are positioned between the first and second closure means. One or more transfer ducts (possibly with their own closure means) located between the driver chamber and the volume of gas between the first and second
25 closure means, may be used to facilitate a more controlled and uniform entrainment of particles and flow initiation.

Embodiments of needleless syringe device in accordance with the present invention will now be described, by way of example only, with reference to the accompanying drawings in which:

30 Figure 1 shows schematically an $x-t$ diagram which describes the flow regimes present in a prior art device similar to the ones described in Bellhouse et al;

Figure 2 shows a cross-sectional view of the nozzle and the instantaneous axial velocity of particles exiting the above-mentioned prior art device after 177 μ s of flow;

Figure 3 shows schematically an $x-t$ diagram which describes the flow regimes present in a device according to a first embodiment of the present invention;

Figure 4 shows a schematic cross-sectional side elevation of a target surface and an impingement region;

Figure 5 shows a needleless injection device according to a first embodiment of the present invention in schematic cross-sectional side elevation;

Figure 6 shows a part of a schematic $x-t$ diagram which describes the behaviour of the starting process in a device according to a second embodiment of the present invention when the gas in region 2 is subsonic and in region 3 is supersonic;

Figure 7 shows a part of a schematic $x-t$ diagram which describes the behaviour of the starting process in a device according to a third embodiment of the present invention when the gas in regions 2 and 3 is subsonic;

Figures 8a and 8b are schematic cross-sectional (before and after) side elevations of the membrane region of a duct section of a fourth embodiment of a needleless injection device and illustrate a further aspect of the invention wherein the duct section has an enlarged duct portion to keep a more constant cross-sectional area after membrane bursting;

Figure 9 shows a fifth embodiment which is a modification to the Figure 5 embodiment wherein the driver chamber has a larger cross-sectional area than the duct section, only part of the device being shown;

Figures 10a, 10b and 10c are a sequence of schematic cross-sectional side elevations of the membrane region of a sixth embodiment of a needleless injection device and show another aspect of the invention relating to the creation of a mixed gas-particle cloud between two closures in a driver chamber;

Figures 11a, 11b, 11c, 11d and 11e show a seventh embodiment which involves a similar sequence to Fig. 10 except the rupture pressures and timing of the particle entrainment are different;

Figures 12a, 12b and 12c are a sequence of schematic cross-sectional side elevations of the membrane region of an eighth embodiment and show the use of a transfer duct and a separate rupturable membrane to create a mixed gas-particle cloud between two closures in the driver chamber; and

5 Figures 13a, 13b, and 13c are a sequence of schematic cross-sectional side elevations of the membrane region of a modification of the eighth embodiment in which the transfer duct is positioned in the upstream closure means.

Embodiment 1

10

The first embodiment of the invention is an air powered, disposable device and is shown schematically in Figure 5. The device could, however, be reusable and/or powered by a fluid other than air, for example helium, nitrogen or a mixture of gases. The selection of gas can be used to tune the performance of the device.

15 Different gases or gas mixtures provide different quasi-steady gas velocities in the same device and so the target particle velocity can be closely controlled by an appropriate driver gas selection.

The device comprises an elongate tubular driver chamber 51 attached to a cylindrical duct section (or shock tube) 52 of the same diameter as the driver
20 chamber 51. In this embodiment, each tube has a 6mm diameter, but in general the diameters can be different to one another and can be of any practical size.

In this embodiment, the driver chamber 51 has a length L_D of 65 mm and the duct section 52 has a length L_I of 30 mm. Other lengths are possible, and in fact the determination of the lengths is thought to be important in influencing the
25 performance of the device (see later).

At the interface between the driver chamber 51 and duct section 52 is a rupturable membrane 53. The membrane 53 is of the type disclosed in Bellhouse et al and typically ruptures with a pressure difference across it in a range from around 5 to 20 bar, preferably 10 to 15 bar. The rupture pressure is an important device
30 parameter but other rupture pressures could also be used depending on the desired results. Control of the rupture process can be important for mixing and flow uniformity and may be enhanced by the prior indentation or scoring of the

membrane, preferably along radial lines along which the rupture will propagate. This provides for more symmetrical membrane opening which in turn can provide a more symmetrical particle distribution at the target plane.

The downstream end of the duct section 52 is provided with a contoured
5 divergent nozzle 54 in this embodiment. The nozzle 54 has an area ratio A_e/A_1 such that correctly expanded flow is established within it when the membrane 53 has ruptured and the driver chamber 51 discharges. In practice this ratio (A_e/A_1) could range from 1 to 50. As drawn, the contoured nozzle 54 could be of conical shape with a half angle which is not so steep as to cause flow separation. Half angles up to 15°
10 could be used in practice, and it has been found that 6° operates satisfactorily. The divergent nozzle 54 could take other forms and, in fact, is not essential to the present invention.

The driver chamber 51 is connected at its upstream end to a reservoir 55 of pressurised gas (in this case air) by a small diameter bleed hole 56. Other gases or
15 gas mixtures which are sterile and easily obtainable such as helium, nitrogen, argon or CO₂ are also suitable. The gas pressure in the reservoir 55 should be sufficient for the gas to be able to pass into the driver chamber 51 and rupture the membrane 53. In this embodiment the gas pressure is 60 bar but could be higher or lower depending on the membrane rupturing pressure. Also, other energising means (such as
20 explosive charges) could be used to discharge gas into the driver chamber 51.

The reservoir 55 may be connected to the bleed hole 56 in a standard way (such as with a valve 57 as shown in the Figure) such that a flow of gas from the reservoir 55 to the driver chamber 51 can be initiated on demand. In this
embodiment the bleed hole 56 has a diameter of 0.4 mm. This effectively de-couples
25 the reservoir 55 and driver chamber 51 during the period of device operation (for an explanation of de-coupling, see below). However, other sizes of bleed hole could be used (for e.g. from 0.1 mm to 5 mm). When larger holes are used, total decoupling would not be established and the total pressure P_{tot} in the driver chamber 51 would be able to rise as the device is actuated (with de-coupling, the total pressure remains
30 constant).

As a further alternative, the driver chamber 51 could be pre-charged with pressurised gas and the reservoir 55 omitted. In such an arrangement, the membrane 53 could be punctured mechanically to actuate the device.

The particles 58 to be accelerated are in this embodiment initially located in the driver chamber 51 in the region of the rupturable membrane 53. The particles 58 do not necessarily have to be initially located adjacent to the membrane 53. If they are located anywhere in the driver chamber 51 initially, they will not be entrained in the starting transient and so the invention should still operate. Also, the particles 58 could be located adjacent to the downstream side of the membrane 53 and the device should still work.

The functioning of this device is shown schematically by the $x-t$ diagram in Figure 3, with $t=0$ corresponding to membrane rupture. When the reservoir valve 57 is opened, gas flows from the reservoir 55 to the driver chamber 51 via the bleed hole 56 until the membrane rupture pressure is reached in the driver chamber 51. Thus, upon rupturing of the membrane 53, a shock 31 is generated which travels down the duct section 52 in the downstream direction. After a characteristic shock formation distance, the shock 31 travels ahead of the contact surface 32 at a constant speed. The contact surface 32 follows closely behind the shock 31 and the particles 33 follow behind that. Three flow regions can be identified:

- i) Quiescent gas ahead of the shock wave 31 (region 1)
- ii) Gas between the shock 31 and the contact surface 32 (region 2)
- iii) Gas between the contact surface 32 and the particles 33 (region 3)

The distance between the particles 33 and the contact surface 32 increases initially with time because of the slower acceleration of the particles compared with the gas. The function of the duct section 52 is to provide a distance over which the shock 31 and the contact surface 32 can form so that the separation between the shock 31 (which will initiate the starting process at the transition between the duct 52 and the divergent nozzle 54), i.e. the "Nozzle Start" position in Fig. 3, and the particles 33 increases. The instantaneous delay time t_D (the time between the starting process initiating and the particles reaching the divergence 54) is a function of the particle size and gas type, whereby larger and denser particles are delayed more.

Simultaneously to the above, a first $(u-a)$ expansion wave 34 moves at a constant velocity (initially the speed of sound in the gas, a) from the location of the ruptured membrane 53 in the upstream direction until it reaches the bleed hole 56. Here it is reflected back as a $(u+a)$ wave 36 in the downstream direction where it
5 accelerates until it eventually exits through the nozzle 54. The gas velocity in the downstream direction is denoted by u and the local speed of sound in the gas is denoted by a . Further $(u-a)$ expansion waves are created and the result is unsteady expansion fan 30 shown in Figure 3.

As the shock 31 moves through the tube in region 2, it serves to process the
10 quiescent gas in region 1 to be in region 2 and heats up the this gas it processes, increasing its temperature and density. This is the so-called "shock-heating" process.

When the shock 31 reaches the start of the divergent nozzle 54, the starting process is initiated and a second $(u-a)$ wave 35 is produced at the transition between the constant area 52 and divergence 54. In the embodiment of Figure 3, the driver
15 gas is such and the pressure is sufficiently high for the Mach number of the gas in both regions 2 and 3 to be greater than 1. This second $(u-a)$ wave 35 travels relatively slowly along the nozzle 54 in the downstream direction and accelerates once the contact surface 32 has overtaken it. This occurs because the gas ahead of the contact surface 32 in region 2 has been shock-heated by the passing of the shock-
20 wave and so has a higher temperature and speed of sound than the gas behind the contact surface 32 in region 3. The gas in region 3 has been cooled by the expansion wave 34. Thus, when the second $(u-a)$ wave 35 is overtaken by the contact surface 32, it speeds up in the downstream direction because the value of a drops suddenly (whereas the value of the velocity, u , is matched across the contact surface 32). The
25 shock heating and expansion cooling processes are therefore beneficial in containing and in accelerating the starting process out of the device.

As the shock 31 propagates in the divergent section there is a complex system of $(u-a)$ waves established. This system of waves 37 is downstream of the $(u-a)$ wave 35 in this example. The waves 37 are required to match the flow upstream of
30 the shock 31 and the quasi-steady supersonic flow in the divergent nozzle 54. This system of waves 37 generally coalesces to form a secondary shock wave 38. As

shown in Figure 3 the second ($u-a$) wave 35 and the downstream system of waves 37 and 38 may pass into region 3.

The length L_I of the duct section 52 is chosen so that the bulk of the particle cloud 33 is accelerated in the diverging duct 54 by a quasi-steady supersonic flow.

5 This can be achieved by ensuring that the secondary shock 38 precedes, and leaves the diverging duct ahead of, the particle cloud. Quasi-steady flow is a substantially steady flow and in particular in this application is a flow substantially free of shock waves. Expansion waves (such as ($u-a$) wave 35) may be present in this quasi-steady flow.

10 In other words, the device is arranged so that the final delay time t_f (the time between the secondary shock 38 and the head of the particle cloud 33) is positive.

Further, the length L_I of the duct section 52 is also important for the reason that, the longer it is, the more the particles 33 are accelerated and approach the gas velocity. The gas in region 3 has a uniform density and velocity so the particles 33
15 experience a uniform acceleration due to the difference between their velocity and that of the gas.

A long length L_I would theoretically lead to particle velocities close to the gas velocity. However, in practice, increasing the length L_I to beyond a certain point will give diminishing returns due to shock attenuation and the contact surface 32
20 moving closer to the shock wave 31 as a result of boundary layer growth at the duct walls. There is therefore an optimum duct length of L_I which also depends on the other parameters (such as the driver gas species and pressure), and other constraints of the system.

The length L_D of the driver chamber 51 is chosen so that the particles 58 have
25 passed out of the device before the reflected expansion wave 36 passes out of the device. In other words, the length is preferably chosen so that the reflected expansion wave 36 nominally does not overtake the bulk of particle cloud 33. This length ideally needs to be longer if light gases are used in the driver chamber (e.g. helium) which have a higher speed of sound. Thus, the boundary in time between the
30 point where the shock wave 38 arrives at the divergent nozzle exit (effectively terminating the starting process) and the point where the reflected first ($u-a$) wave 36 arrives at the nozzle exit delimit a regime of clean, quasi-steady flow. Substantially

all of the particles 58 are entrained in this regime of clean flow (otherwise termed as the particle “delivery window”).

Upon actuation, the bleed hole 56 causes the driver chamber 51 to be filled gradually until the membrane rupture pressure is reached. The bleed hole 56 (which
5 could be constituted by an orifice plate) serves to ensure that during the discharge process, a negligible amount of gas is able to escape from the reservoir 55 into the driver chamber 51. The bleed hole 56 therefore effectively creates an end-wall condition and has the effect of de-coupling the reservoir 55 from the flow system. Thus, the static pressure P_{static} in the driver chamber 51 remains substantially
10 constant throughout the time the particles are accelerated. In this embodiment, the static pressure P_{static} in the driver chamber 51 is the membrane rupture pressure. The atmospheric (or ambient) exit pressure initially at the nozzle exit is denoted by P_e . The ratio P_3/P_e (P_3 is the static pressure in region 3) is matched via analytical equations to the ratio A_1/A_e to ensure a quasi-steady correctly expanded flow through
15 the nozzle section 54. Since the total pressure is constant, the nozzle 54 will be correctly expanded for the duration of the particle delivery window resulting in attached flow for substantially the whole actuation period. The flow is therefore clean and attached for the period in which particles 58 are entrained. The above description relates to a correctly expanded nozzle. However, the system is robust and
20 experiments have shown that substantially clean and attached flow can also be obtained with an under-expanded nozzle or even a slightly overexpanded nozzle. A correctly expanded nozzle is preferred though.

The bleed hole 56 also makes the device easier to silence because it restricts gas flowrate from the reservoir 55.

25 Ensuring that the particles 58 are entrained in the quasi-steady flow is believed to provide a further advantage. When a flow impinges on a flat area 41 (in this case the skin or other tissue), an “impingement region” (see Figure 4) is set up. This region comprises a stagnation bubble 42 which serves to reduce the speed of the particles 58 as they approach the surface of the skin 41. Ideally, the nozzle exit is
30 maintained at a predetermined distance from the target plane by a spacer (not shown in Figure 4). The quasi-steady flow expanded from region 3 within the divergent duct is a supersonic flow and it is slowed down in the impingement region by a shock

wave 43. With the correctly expanded divergent nozzle, this supersonic flow forms a parallel jet at the exit and thus creates an essentially normal shock 43 in the impingement region. This controlled impingement region ensures that the drug particles 58 maintain uniform velocities from the jet centreline to the outer edges as they decelerate after passing through the shock and before impacting the skin or tissue target.

Embodiment 2

10 In the above embodiment, the gas flow in both regions 2 and 3 is supersonic (i.e. it has a Mach number, $M > 1$). However it is to be noted that the device also works when the gas in region 2 has a Mach number of less than 1. In this case, the nature of the starting process is altered as is shown in Figure 6, where identical reference numerals correspond to similar features. Here, the $(u-a)$ wave 35 initially
15 travels upstream (because u is now smaller than a). This $(u-a)$ wave 35 and subsequent $(u-a)$ waves 37 are reflected and transmitted at the contact surface 32 as $(u+a)$ and $(u-a)$ waves respectively (only the transmitted $(u-a)$ waves are shown in Figure 6). The complex system of waves 37 coalesces to form again a secondary shock 38.

20 Therefore the net effect of $M < 1$ in region 2 is a shift in the time of arrival at the nozzle exit of the secondary shock 38 (which effectively terminates the starting process). This can be seen by comparing Figures 3 and 6 wherein shock 38 arrives later in Figure 6 than in Figure 3, giving a reduced value of t_f in Figure 6. This simply changes the duration of the delimited regime of clean flow (the delivery
25 window) between the arrival of the secondary shock 38 and the arrival of the first reflected $(u-a)$ wave 36 (not shown in Figure 6).

Embodiment 3

30 A further possibility for device operation occurs when the flow in region 3 has a Mach number of less than 1.

If the driven gas is air and the driver duct 51 is initially provided with:

- air (or nitrogen, or other gases with comparatively high molecular weights) with a closure means breaking at a sufficiently low pressure, or;
- a gas species other than air with a higher speed of sound than air;

then it is possible for the flow in region 3 to have a Mach number of less than 1 (see Figure 7). In this third embodiment, the gas in region 3 will expand to Mach 1 via a second unsteady expansion fan 71 initiated at the start of the nozzle divergent section 54, provided that the driver total pressure is above a critical value. This expansion fan 71 brings the gas to sonic velocity at the upstream end of the divergent section 54. This sonic gas then expands quasi-steadily as a supersonic flow in the divergent section, as described in the earlier two embodiments. Furthermore, the starting process described in the earlier embodiments is present here, with the details dependent upon whether the flow in region 2 is greater or less Mach 1. The flow in region 2 is subsonic in Figure 7. Thus a delivery window of quasi-steady flow, substantially correctly expanded and uniform, is achieved within which the drug particle payload is nominally entrained.

Embodiment 4

It has been found that the device is quite sensitive to the membrane opening area. Thus, it is desirable that the membrane 53 when ruptured (or any other suitable closure when opened) should present an area substantially identical to the area of the duct section 52. An example of apparatus to achieve this is shown in Figures 8a and 8b. Figure 8a shows the situation before rupture. An annular channel 81 is disposed adjacent to the downstream side of the membrane 53 (shown dashed in Figure 8 but in fact it is non-porous) so that when the membrane 53 ruptures, the area presented to the gas flow is substantially constant (see Figure 8b). If the area presented is smaller, a constriction occurs in the flow resulting in undesirable gas dynamics such as the creation of a steady expansion and flow perturbations.

Embodiment 5

In the above embodiments, the driver chamber 51 is shown as having the same area as the duct section 52. However, the driver chamber 51 could be constructed so as to have a larger area than the duct section 52. This is shown in Figure 9. Such a construction causes a weaker unsteady expansion fan 30 and therefore a weaker reflected $(u+a)$ wave 36. The weaker expansion waves caused by larger driver chamber cross-sectional area cause a smaller disruption to the acceleration of the particles 58 should these waves catch up to some of the particles before entry into the skin tissue or target.

Further, this construction makes the device less sensitive to variations in the membrane opening area. It is to be noted that the driver chamber area A_0 is preferably not less than the duct section area A_1 because this would result effectively in a divergence at the membrane. This would create waves at the point where the particles start and so might be unlikely to allow the starting transient to pass out of the nozzle before the particles 58 are entrained in the gas flow.

Embodiment 6

Another possible aspect of the invention to enhance particle mixing will now be described. Figure 10a shows a device having two membranes(101,102). The particles 58 are initially located between the two membranes in the driver chamber 51. The membranes are constituted so as to have different rupturing pressures, the upstream membrane 101 having a lower rupturing pressure than the downstream membrane 102. As the driver chamber 51 is filled and the upstream rupturing pressure is reached, the first membrane 101 ruptures (see Figure 10b), during which a jet of gas 103 discharges into the volume where the particles 58 are retained. It is thought that this jet 103 causes mixing of the gas and particles to create a gas-particle cloud that is quite uniform (see Figure 10c). Thus, when the downstream membrane 102 ruptures at a higher pressure, the particles 58 are already entrained in a cloud and a more uniform spread of particles is obtained. The delay time caused by the difference in rupturing pressure of the two membranes is sufficient to allow gas-

particle mixing and a cloud to form and thereby overcome possible effects of gravity or attraction between the particles which cause the particles to bunch together (e.g. at the lowest point in the device) before rupture of the downstream membrane 102.

Beneficially, a distance (e.g. a distance greater than one membrane radius) should
5 separate the two membranes to allow for a clean membrane rupture and good mixing.

As a further modification, the particles 58 could initially be located upstream of the upstream membrane 101. When the upstream membrane 101 ruptures, the gas flowing into the space between the membranes carries the particles 58 with it and mixing is thus effected to produce a cloud in the same way as described above.

10

Embodiment 7

A further possible particle entrainment approach will now be described with reference to Figures 11a to 11e. Once again, the particles 58 are initially located
15 between two membranes, however the upstream membrane 111 now has a higher rupture pressure than the downstream membrane 112 (see Figure 11a). As the upstream membrane 111 ruptures over a short but finite time, a jet of gas 113 mixes the particles as it fills the volume, and increases the local pressure (see Figures 11b and 11c). The downstream membrane 112 ruptures during or immediately after the
20 rupture time of the upstream membrane 111 as a result of its lower rupture pressure. The new jet 114 (see Figure 11d) created by this process is weaker than jet 113, and the membrane 112 opens over a shorter rupture time than membrane 111 and results in a more controlled entrainment process (rupture time is determined in part by the unnecessary excess of pressure present in opening the membrane).

25

Embodiment 8

Figures 12a to 12c show stages in operation of an eighth embodiment of the invention, designed to aid particle mixing.

30 As can be seen from Figure 12a, a transfer duct 121 is provided to create a gas channel linking the driver duct to the volume between two membranes 123 and

124. The transfer duct is itself provided with a membrane 122 which ideally has a bursting pressure lower than that of membrane 123.

In operation, gas is fed to the driver chamber and enters the transfer duct. Membrane 122 ruptures when the gas reaches its predetermined bursting level.

5 When membrane 122 ruptures, gas travels along the transfer duct and jets into the space between the membranes 123 and 124 (see Figure 12b). This causes mixing of the gas and particles 58 to create a cloud of gas and particles between the membranes. The membrane 123 then bursts as does membrane 124, the timing being determined by the relative bursting pressures. It can be seen that the transfer duct serves to
10 provide a jet of gas into the volume of particles to cause mixing before membranes 123 and 124 have ruptured.

The membrane 122 is not essential and may be dispensed with, especially if the transfer duct has a very small cross-sectional area so as to be effectively decoupled from the driver duct 51.

15 It is generally necessary for the transfer duct 121 to have a cross-sectional area smaller than the driver duct 51 to ensure that the driver gas does not completely bypass membrane 123 by flowing completely down the transfer duct 121. Further, membrane 122 may have a bursting pressure slightly higher than, or the same as, membrane 123. In this case, the side jet provided by the transfer duct 121 will be
20 provided shortly after or at the same time as the jet provided by the opening of membrane 123.

One or more transfer ducts 121 may be provided in the device and one or some of these transfer ducts could be routed to provide side jets in volumes not initially housing particles.

25 A preferable modification of the above is shown in Figures 13a to 13c of the accompanying drawings. In this modification, the transfer duct consists of a small aperture 134 in the upstream closure means 131. Thus, when a gaseous pressure is exposed to the upstream closure means 131, some gas 133 is routed through the small aperture 134 which acts as a transfer duct prior to membrane rupture. This
30 causes a similar mixing effect to that provided by separate, tubular, transfer ducts.

The upstream membrane 131 has an aperture 134 having a size small enough to prevent any particles escaping. The aperture is preferably circular and centred on

the upstream membrane 131. Alternatively, the transfer duct may be provided by a membrane which is scored so as to burst in two stages; a centrally scored part would firstly rupture to allow a jet of gas 133 to enter the volume between the two membranes and then the rest of the membrane ruptures allowing a quasi-steady gas flow to be established.

The transfer duct 134 may ideally be provided by one or more pin-pricks in the membrane 131 or the central part of the membrane may be comprised of a series of leaf-like flaps which open when a gaseous pressure is applied thereto. Any means which allows gas to enter the volume between the upstream and downstream membrane before the upstream membrane ruptures fully is suitable.

Although in the description above the closure means has taken the form of a rupturable membrane, any other suitable rapidly openable closure means could alternatively be used, such as a non-membrane cassette.

The divergent nozzle 54 could have a simple profile or one that is contoured to ensures that the nozzle gas flow is uniform and free of oblique shocks. In this case, the parallel and uniform nozzle exit flow also sets up a nominally flat impingement shock and a more uniform impingement region.

The invention will still operate satisfactorily if the divergent nozzle 54 is dispensed with completely. In such a case, the gas undergoes a rapid expansion at the downstream end of the duct section 52. This case is equivalent to an under-expanded nozzle operation with a starting process in the downstream free jet which is analogous to the above starting process. Thus, a starting process of sorts is created even in the absence of a divergent nozzle and the concept of the invention is still applicable to devices having no divergent nozzle.

CLAIMS

1. A method of accelerating a dose of particles in a needleless injection device having a driver chamber and a duct section downstream of said driver chamber, the
5 method comprising:
opening closure means located between said driver chamber and said duct section;
producing a primary shock wave travelling in a downstream direction in said duct section;
10 establishing a substantially quasi-steady flow of fluid in said duct section upstream of said primary shock wave; and
entraining and accelerating substantially all the dose of particles in said substantially quasi-steady flow for the duration of time that said particles are in said duct section.
15
2. A method of accelerating a dose of particles in a needleless injection device according to claim 1, wherein the duct section is of substantially constant cross-sectional area and the method further comprises initiating a starting process when said primary shock wave reaches the downstream end of said substantially constant
20 cross-sectional area duct section.
3. A method of accelerating particles according to claim 2, wherein said step of entraining and accelerating said particles is carried out in said duct section of substantially constant cross-sectional area.
25
4. A method of accelerating a dose of particles in a needleless injection device according to claim 1, 2 or 3, further comprising producing a secondary shock wave travelling in a downstream direction behind said primary shock wave.
- 30 5. A method of accelerating particles according to claim 4, wherein said quasi-steady flow is established upstream of said secondary shock wave.

6. A method of accelerating particles according to any one of the preceding claims, wherein said particles are entrained and accelerated from an initial position upstream of said closure means.

5

7. A method of accelerating particles according to any one of the preceding claims, wherein said particles are not accelerated through a constriction downstream of said closure means.

10 8. A method of accelerating particles according to any one of the preceding claims, wherein said closure means is a first closure means and the method further comprises opening a further closure means before opening said first closure means.

9. A method of accelerating particles according to any one of the preceding
15 claims, further comprising directing said quasi-steady flow of fluid through a divergent nozzle positioned downstream of said duct section.

10. A method of accelerating particles according to claim 9, wherein said quasi-steady flow directed through said divergent nozzle portion is substantially correctly
20 expanded.

11. A method of accelerating particles according to claim 9 or 10, wherein said quasi-steady flow directed through said nozzle portion exits the downstream end of said device with a velocity distribution that is substantially uniform over a cross-
25 section thereof.

12. A method of accelerating particles according to any one of claims 9, 10 or 11, wherein said divergent nozzle portion has an internal contour such that substantially no oblique shocks are formed in the part of said quasi-steady flow in which said
30 particles are entrained.

13. A method of accelerating particles according to any one of claims 9 to 12, further comprising spacing said needleless injection device from a target plane; creating a substantially normal shock wave at the exit of said divergent portion;
- 5 decelerating the particles in said substantially normal shock wave so as to have a generally radially uniform velocity as they impact the target plane.
14. A method of accelerating particles according to any one of claims 9 to 13, further comprising the step of initiating a ($u-a$) wave at the downstream end of said
- 10 duct section.
15. A method of accelerating particles according to claim 14, wherein said quasi-steady flow is established upstream of said ($u-a$) wave.
- 15 16. A method of accelerating particles according to any one of the preceding claims, further comprising creating an expansion wave which travels in an upstream direction from the location of said closure means.
17. A method of accelerating particles according to claim 16, further comprising
- 20 reflecting said expansion wave so that it travels in a downstream direction.
18. A method of accelerating particles according to claim 17 wherein said quasi-steady flow is terminated when said reflected expansion wave passes out of the downstream end of the device.
- 25
19. A method of accelerating particles according to any one of the preceding claims, further comprising the step of selecting the driver gas species, or combination of species, so as to control the velocity of the particles as they exit the device.
- 30 20. A needleless injection device comprising:
a driver chamber arranged, in use, to contain a charge of pressurised gas;
a duct section connected to said driver chamber to receive gas therefrom;

closure means for preventing the flow of gas from said driver chamber to said duct section until said closure means is opened; and

a dose of particles positioned within the device in the region of said closure means;

- 5 said device being so constructed and arranged that upon opening of said closure means, a primary shock wave is produced to travel along said duct section in a downstream direction and a substantially quasi-steady gas flow is established in said duct section upstream of said primary shock wave, said dose of particles being substantially wholly entrained in said substantially quasi-steady flow to be
10 accelerated thereby and expelled from the device.

21. A needleless injection device according to claim 20, wherein the device is arranged so that said primary shock wave initiates a transient starting process upon reaching the downstream end of the duct section.

15

22. A needleless injection device according to claim 20 or 21, wherein said closure means is positioned at the downstream extent of said driver chamber.

23. A needleless injection device according to any one of claims 20 to 22,
20 wherein said driver chamber is pre-charged with pressurised gas.

24. A needleless injection device according to any one of claims 20 to 22, further comprising a source of gaseous fluid, said driver chamber being fluidly connected to said source and arranged to be provided with said charge of pressurised gas by said
25 source upon opening of the fluid connection therebetween.

25. A needleless injection device according to claim 24, wherein said fluid connection consists of a bleed hole of a size small enough substantially to de-couple said driver chamber from said source of gaseous fluid upon opening of said closure
30 means.

26. A needleless injection device according to any one of claims 20 to 25, wherein said duct section comprises a tube of substantially constant cross-sectional area.
- 5 27. A needleless injection device according to any one of claims 20 to 26, in which said particles are positioned upstream of said closure means.
- 28 A needleless injection device according to any one of claims 20 to 27, wherein said duct section includes substantially no convergent portion therein
10 downstream of said closure means.
29. A needleless injection device according to any one claims 20 to 28, further comprising a divergent nozzle portion positioned downstream of said duct section.
- 15 30. A needleless injection device according to claim 29, wherein said divergent nozzle portion has an inlet cross-sectional area and an exit cross-sectional area, said areas being chosen in accordance with the total driver chamber pressure at which said device is arranged to operate so that, in use, the gas flow in said divergent portion is substantially correctly expanded when said particles pass through said divergent
20 portion.
31. A needleless injection device according to claim 29 or 30, wherein said divergent nozzle portion has an internal contour such that substantially no oblique shock waves are formed in said substantially quasi-steady flow.
25
32. A needleless injection device according to any one of claims 29 to 31, wherein said divergent nozzle portion is contoured such as to cause any expansion downstream of the duct section to provide a generally radially uniform particle distribution at the exit of the divergent portion and a generally radially uniform
30 particle velocity distribution, with a substantially parallel velocity of particles and gas exiting the device.

33. A needleless injection device according to any one of claims 29 to 32, further comprising a spacer positioned at the downstream end of the device, the spacer being constructed so as to space a target plane downstream of the divergent nozzle portion exit with a clearance sufficient to allow:
- 5 a substantially normal shock wave to be positioned downstream of the exit of said divergent nozzle portion; so that
- said normal shock interacts, in use, with the gas and particle jet from said device to provide a substantially controlled and uniform gas stagnation region which decelerates the particles to a generally uniform velocity as they impact the target
- 10 plane.
34. A needleless injection device according to any one of claims 20 to 37, wherein said driver chamber comprises a substantially constant area tube.
- 15 35. A needleless injection device according to any one claims 20 to 34, wherein said driver chamber comprises a convergence at its downstream end, positioned upstream of said closure means.
36. A needleless injection device according to any one claims of claims 20 to 35,
- 20 wherein said closure means comprises a rupturable membrane arranged to open by rupturing.
37. A needleless injection device according to claim 36, wherein said rupturable membrane is arranged to rupture in a controlled way due to an indentation on, or
- 25 scoring of, the membrane surface.
38. A needleless injection device according to any one claims 20 to 37, wherein said device contains a further closure means.
- 30 39. A needleless injection device according to claim 38, wherein said further closure means is positioned in said driver chamber upstream of said particles.

40. A needleless injection device according to claim 38 or 39, wherein said further closure means comprises a rupturable membrane arranged to open by rupturing.

5

41. A needleless injection device according to claim 40, wherein said rupturable membrane is arranged to rupture in a controlled way due to an indentation on, or scoring of, its surfaces.

10 42. A particle retention assembly of or for use in a needleless injection device; said assembly comprising:

first closure means arranged to open when the pressure across it is P_1 ; and

second closure means which, in use, is located upstream of said first closure means and which is arranged to open when the pressure across it is P_2 ;

15 wherein P_1 and P_2 are different.

43. An assembly according to claim 42, wherein P_1 is greater than P_2 .

44. An assembly according to claim 42, wherein P_2 is greater than P_1 .

20

45. A particle retention assembly of or for use in a needleless injection device; said assembly comprising:

first closure means arranged to open when the pressure across it is P_1 ;

second closure means which, in use, is located upstream of said first closure

25 means and which is arranged to open when the pressure across it is P_2 ;

a transfer duct which fluidly connects a location upstream of said second closure means to a location between said first and second closure means.

46. A particle retention assembly according to claim 45, wherein said transfer
30 duct is arranged to direct a jet of gas from upstream of said second closure means so as to impinge on any particles located between said first closure means and said

second closure means so as to create a gas/particle cloud between said first and second closure means.

47. A particle retention assembly according to claim 45 or 46, further comprising
5 transfer duct closure means in said transfer duct.

48. A particle retention assembly according to claim 47, wherein said transfer duct closure means is arranged so as to open when the pressure across it is P_T , wherein P_T is less than P_2 .

10

49. A particle retention assembly according to any one of claims 45 to 48, wherein said transfer duct is positioned in said second closure means.

50. A particle retention assembly according to any one of claims 42 to 49, further
15 comprising a dose of particles located between said first and second closure means.

51. A particle retention assembly according to any one of claims 42 to 50, wherein some or all of said various closure means are each constituted by a rupturable membrane which is scored or indented to provide controlled rupturing.

20

52. A particle retention assembly of or for use in a needleless injection device; said assembly comprising:

first closure means arranged to open when the pressure across it is P_1 ;

second closure means which, in use, is located upstream of said first closure
25 means and which is arranged to open when the pressure across it is P_2 ;

wherein one of said first and second closure means are constituted by rupturable membranes which are scored or indented so as to provide controlled rupturing.

30 53. A particle retention assembly according to claim 52, wherein said scored or indented rupturable membrane is scored or indented along one or more radial lines.

54. An assembly according to any one of claims 42 to 53, wherein the assembly is of, or for use in, a needleless injection device having the construction claimed in any of claims 20 to 41.

5 55. A needleless injection device comprising the assembly of any one of claims 42 to 54.

56. A method of needleless injection involving the injection of particles into bodily tissue, the method comprising accelerating the particles in a needleless
10 injection device using the method of particle acceleration claimed in any one of claims 1 to 19.

57. A method of entraining a dose of particles in a gas flow in a needleless injection device, the method comprising:

15 opening an upstream closure means when the pressure difference thereacross is P_2 to produce a cloud of gas;

entraining said particles in said cloud of gas; and

opening a downstream closure means when the downstream closure means is exposed to said cloud of gas and entrained particles and when the pressure difference
20 across said downstream closure means is P_1 ;

wherein P_1 is different to P_2 .

58. A method of entraining a dose of particles in a gas flow in a needleless injection device, the method comprising:

25 providing a duct having upstream and downstream closure means;

providing a transfer duct which is arranged to permit gas from upstream of said upstream closure means to be introduced into the space between said upstream closure means and said downstream closure means.

30 59. A method of entraining a dose of particles according to claim 58, further comprising causing a jet of gas to impinge on any particles located between said upstream closure means and said downstream closure means so as to create a

gas/particle cloud between said upstream closure means and said downstream closure means.

60. A method of entraining a dose of particles according to claim 58 or 59,
5 further comprising providing a transfer duct closure means in said transfer duct.

61. A method of entraining a dose of particles according to claim 60, further
comprising opening said transfer duct closure means when the pressure across it is
 P_T , this pressure being less than the pressure at which said upstream closure means
10 opens at.

62. A method of entraining a dose of particles according to any one of claims 58
to 61, further including the steps of allowing gas to pass through a small aperture in
said upstream closure means; and
15 causing said upstream closure means to rupture after some gas has passed
therethrough into said space between said upstream and downstream closure means.

63. A method of needleless injection involving the injection of particles into
bodily tissue, the method comprising entraining the particles in a gas flow in a
20 needleless injection device using a method of particle entrainment according to any
one of claims 58 to 62.





FIG. 2



27

FIG. 3





FIG. 4



3/7

FIG. 5




FIG. 6




FIG. 7




FIG.8a




FIG.8b





FIG. 9






FIG. 10a




FIG. 10b




FIG. 10c




FIG. 12a




FIG. 12b




FIG. 12c

6/7




FIG. 11a




FIG. 11b




FIG. 11c




FIG. 11d




FIG. 11e




FIG. 13a




FIG. 13b




FIG. 13c

INTERNATIONAL SEARCH REPORT

In [REDACTED] Application No

PCT/GB 00/02257

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61M5/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M C12M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 25190 A (OXFORD BIOSCIENCES LTD ;BELLHOUSE BRIAN JOHN (GB); BELL JOHN (GB);) 22 August 1996 (1996-08-22)	1-6, 9, 10, 16-18, 20-24, 26, 35, 36, 38-40
A	the whole document	7, 25
A	WO 97 47730 A (AURAGEN INC) 18 December 1997 (1997-12-18) claims 1-3; figures 1, 2	1, 20
A	EP 0 821 195 A (BOC GROUP PLC) 28 January 1998 (1998-01-28) column 4, line 22 - line 24 figure 3	27, 34, 36

-/-

Y Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

2 document member of the same patent family

Date of the actual completion of the international search

9 November 2000

Date of mailing of the international search report

21 11 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sedy, R

INTERNATIONAL SEARCH REPORT

Ir Application No

PCT/GB 00/02257

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 5 899 880 A (BELLHOUSE BRIAN J ET AL) 4 May 1999 (1999-05-04) column 4, line 30 - line 34 column 9, line 60 -column 10, line 8 figures 1,8,8A</p>	<p>42,45, 52,57,58</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/02257

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 56, 63
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-19,20-41

Claims 1-19: method of accelerating a dose of particles in a needleless injection device;

Claims 20-41: needleless injection device.

(object: enabling dose particles to be penetrable through skin)

2. Claims: 42-44,45-51,52-55,57,58-62

method and particle retention assembly comprising two closure means having different rupturing pressures

(object: enhanced particle mixing, see page 19, line 20)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02257

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9625190	A	22-08-1996	AU 4671896 A	04-09-1996
			CA 2211572 A	22-08-1996
			EP 0809521 A	03-12-1997
			JP 11500019 T	06-01-1999
			US 6010478 A	04-01-2000
			AU 699463 B	03-12-1998
			AU 4271496 A	19-07-1996
			BG 101600 A	27-02-1998
			BR 9510464 A	29-06-1999
			CZ 9701937 A	12-11-1997
			DE 69511723 D	30-09-1999
			DE 69511723 T	16-03-2000
			DK 799064 T	20-03-2000
			EP 0799064 A	08-10-1997
			FI 972554 A	16-06-1997
			GR 3031582 T	31-01-2000
			JP 10512467 T	02-12-1998
			NO 972897 A	20-06-1997
			NZ 297542 A	28-10-1999
			PL 320919 A	10-11-1997
			RU 2135219 C	27-08-1999
			SK 81797 A	04-03-1998
WO 9747730	A	18-12-1997	AU 3397597 A	07-01-1998
			CA 2257141 A	18-12-1997
			EP 0907718 A	14-04-1999
			US 6053889 A	25-04-2000
EP 0821195	A	28-01-1998	AU 716664 B	02-03-2000
			AU 2870297 A	05-02-1998
			CA 2209406 A	24-01-1998
			CZ 9702170 A	18-02-1998
			HU 9701213 A	28-12-1998
			JP 10078198 A	24-03-1998
			NZ 328263 A	25-11-1998
			PL 321250 A	02-02-1998
			SK 97697 A	04-03-1998
			US 6047865 A	11-04-2000
US 5899880	A	04-05-1999	AU 674742 B	09-01-1997
			AU 6435194 A	08-11-1994
			BG 61993 B	30-12-1998
			BG 100047 A	30-04-1996
			BR 9406455 A	02-01-1996
			DE 69401651 D	13-03-1997
			DE 69401651 T	15-05-1997
			EP 0693119 A	24-01-1996
			FI 954788 A	06-10-1995
			GR 3022939 T	30-06-1997
			HK 1000351 A	06-03-1998
			JP 8509604 T	15-10-1996
			NO 953994 A	06-10-1995
			PL 311005 A	22-01-1996
			RU 2129021 C	20-04-1999
			SI 693119 T	31-10-1997
			SK 124895 A	08-01-1997

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference N77399A NP/MPR		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/02257	International filing date (day/month/year) 09/06/2000	Priority date (day/month/year) 16/07/1999	
International Patent Classification (IPC) or national classification and IPC A61M5/30			
Applicant POWDERJECT RESEARCH LIMITED et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 7 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 12/02/2001	Date of completion of this report 16.10.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Ceccarelli, D Telephone No. +49 89 2399 2653 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02257

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-22 as originally filed

Claims, No.:

1-63 as originally filed

Drawings, sheets:

1/7-7/7 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB00/02257

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 13-19,56.

because:

☒ the said international application, or the said claims Nos. 13-19,56 relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 56.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

☐ restricted the claims.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02257

- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☒ neither restricted nor paid additional fees.
2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
- ☐ not complied with for the following reasons:
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☐ all parts.
- ☒ the parts relating to claims Nos. 1-41,56.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-12,20-41
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-12,20-41
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-12,20-41
	No:	Claims	

2. Citations and explanations see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. Claim 56 has not been examined according to Article 33(1) PCT, as it defines a method for treatment of the human or animal body (Rule 67.1(iv) PCT). Moreover no meaningful opinion could be given for said claim 56, since no Search Report has been established for it (Rule 66.1(e) PCT).
2. Claims 13-19 also define methods for treatment of the human or animal body (Rule 67.1(iv) PCT), therefore no examination has been carried out for them. As a matter of fact, in the light of the description the "target plane" introduced in claim 13 can only be the skin or other tissue of a patient, as the application deals with a needleless syringe for injections into a "target tissue of a subject" (see page 1, lines 3-4 and page 16, lines 26-27). Claims 14-19 can depend on claim 13.

Re Item IV

Lack of unity of invention

1. This application is deemed to comprise multiple groups of inventions; therefore it does not meet the requirements for unity of invention, as set forth in Rule 13.1 PCT.

The separate groups of inventions are considered to be:

- I) claims 1-41 and 56, which essentially define a needleless injection device comprising a driver chamber, a duct section, closure means and a dose of particles to be delivered and a methods of accelerating particles with a needleless injection device;
they address the objective technical problem of delivering particles by the means of a substantially quasi-steady flow of gas (see claims 1 and 20);
- II) claims 42-55 and 57-63, which essentially define a particle retention assembly comprising first and second closure means and a transfer duct and methods of creating a mixture of gas and particles to be delivered via a

needleless injection device;
they address the objective technical problem of providing an injection device with a cloud of gas and entrained particles in order to enable substantially all of the particles to be entrained in a quasi-steady supersonic flow with high and uniform particle velocities (see also lines 14-17 on page 6).

No special technical features are common to the first and the second group of claims; even the closure means mentioned in each group have different purposes.

Therefore the requirement of unity is not fulfilled, according to Rule 13.2 PCT.

As requested in the applicant's letter of reply of 19.04.2001 following the invitation to restrict the claims of pay additional fees according to Rule 68.2 PCT, only claims 1-12 and 20-41 could be examined.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. This application deals with needleless injectors.
2. The closest prior art is represented by document US-A-5 899 880 (hereinafter referred to as D1).
It discloses a method of accelerating drug particles in a needleless injector comprising the steps of bursting a membrane by a pressurised gas which will then produce a supersonic flow entraining the drug particles in a duct of the injector (see lines 35-44 in column 1).
The subject matter of present claim 1 differs therefrom in that the drug particles are essentially meant to be entrained in the duct in a quasi-steady flow condition, which is generated after a primary shock wave.
This results in a more concentrated particle jet with a more uniform velocity profile.
In the disclosure of document D1 the particles are intended to "closely follow" the

shock wave, the velocity of which should be high in order for the particle jet to be effectively used for injections (see lines 50-65 in column 4).

The other available documents do not mention the possibility of entraining the drug particles in a quasi-steady flow condition.

Therefore claim 1 seems to meet the requirements of Article 33(2) and (3) PCT, regarding novelty and inventive step.

Claims 2-12 depend on claim 1 and add only optional features to its subject matter, therefore they also appear to meet the requirements of Article 33(2) and (3) PCT.

3. Independent claim 20 defines an injector which is "so constructed and arranged" that the flow conditions defined in method claim 1 are attained.
Therefore claim 20 as well as claims 21-41 which depend on it also seem to meet the requirements of Article 33(2) and (3) PCT.

Re Item VII

Certain defects in the international application

1. Document D1 should have been cited in the description, since it represents the closest state of the art in the field of the application (Rule 5.1(a)(ii) PCT).
2. The independent claims are not drafted in the two-part form, as normally required by Rule 6.3(b) PCT.
3. The claims do not contain any reference signs to the figures, which would be appropriate to facilitate the understanding of the claims themselves (Rule 6.2(b) PCT).